Cas:2050-99-9 2,8-dimethylnonan-5-one manufacturer & supplier

We serve Chemical Name:2,8-dimethylnonan-5-one CAS:2050-99-9 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

2,8-dimethylnonan-5-one

Chemical Name:2,8-dimethylnonan-5-one
CAS.NO:2050-99-9
Synonyms:DIISOAMYL KETONE;2,8-Dimethyl-nonan-5-on;5-Nonanone,2,8-dimethyl;isobutyl-methyl ketone;Diisopentylketon;2,8-Dimethyl-5-nonanone;2,8-dimethyl-nonan-5-one
Molecular Formula:C11H22O
Molecular Weight:170.29200
HS Code:2914190090

Physical and Chemical Properties:
Melting point:N/A
Boiling point:208.9ºC at 760mmHg
Density:0.818g/cm3
Index of Refraction:1.422
PSA:17.07000
Exact Mass:170.16700
LogP:3.42790

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like DIISOAMYL KETONE chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2,8-dimethyl-nonan-5-one physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2,8-Dimethyl-nonan-5-on Use and application,2,8-Dimethyl-5-nonanone technical grade,usp/ep/jp grade.


Related News: In addition, the manufacturing process of MSP-1014 precludes the phosphorylation step, one of the most challenging chemical synthesis steps in psilocybin manufacturing. (2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)chroman-3-yl 2-methyldecanoate manufacturers “The acquisition of Vanamali Organics represents the next stage of this investment strategy,” Wavelength CEO Iftach Seri said in a statement. ” We are delighted to add their talented team and advanced development and manufacturing capabilities to Wavelength, and we expect they will be important contributors to our global supply chain network and our rapidly growing custom development and manufacturing services business.” 9-cyano-9-(3-(N-methyl-N-homoveratryl-1-propylamino))fluorene perchlorate suppliers In the trial, 362 eligible patients were randomised (1:1) and received a fixed-dose intravenous infusion of 300mg anifrolumab or placebo every four weeks. (4-methanesulfonyl-2,2-dimethyl-cyclobutyl)-dimethyl-amine vendor & factory.